John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Kirkwood F Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen, Michael Böhm, Diana Bonderman, John G F Cleland, Ramon Corbalan, Maria G Crespo-Leiro, Ulf Dahlström, Rafael Diaz, Luis E Echeverria Correa, James C Fang, Gerasimos Filippatos, Cândida Fonseca, Eva Goncalvesova, Assen R Goudev, Jonathan G Howlett, David E Lanfear, Mayanna Lund, Peter Macdonald, Vyacheslav Mareev, Shin-Ichi Momomura, Eileen O'Meara, Alexander Parkhomenko, Piotr Ponikowski, Felix J A Ramires, Pranas Serpytis, Karen Sliwa, Jindrich Spinar, Thomas M Suter, Janos Tomcsanyi, Hans Vandekerckhove, Dragos Vinereanu, Adriaan A Voors, Mehmet B Yilmaz, Faiez Zannad, Lucie Sharpsten, Jason C Legg, Siddique A Abbasi, Claire Varin, Fady I Malik, Christopher E Kurtz
AIMS: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. METHODS AND RESULTS: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37...
September 27, 2020: European Journal of Heart Failure
Robert J Mentz, Haolin Xu, Emily C O'Brien, Laine Thomas, Tamas Alexy, Bhanu Gupta, Juan Vilaro, Anuradha Lala, Adam D DeVore, Ravi Dhingra, Alexandros Briasoulis, Marc A Simon, Josef Stehlik, Jo E Rodgers, Shannon M Dunlay, Martha Abshire, Quinn S Wells, Kurt G Barringhaus, Peter M Eckman, Brian D Lowes, Johana Espinoza, Rosalia Blanco, Xian Shen, Carol I Duffy, Adrian F Hernandez
BACKGROUND: In PARADIGM-HF, sacubitril/valsartan improved quality of life (QOL) vs. enalapril in heart failure with reduced ejection fraction (HFrEF), yet limited data are available regarding QOL changes after sacubitril/valsartan initiation in routine practice. METHODS: PROVIDE-HF was a prospective study within a national research network (PCORnet) of HFrEF outpatients recently initiated on sacubitril/valsartan vs. controls with recent ACE-I/ARB initiation/dose change...
September 24, 2020: American Heart Journal
Raj M Khandwalla, Daniel Grant, Kade Birkeland, J Thomas Heywood, Emmanuel Fombu, Robert L Owens, Steven R Steinhubl
BACKGROUND: AWAKE-HF evaluated the effect of the initiation of sacubitril/valsartan versus enalapril on activity and sleep using actigraphy in patients who have heart failure with reduced ejection fraction (HFrEF). METHODS: In this randomized, double-blind study, patients with HFrEF (n = 140) were randomly assigned to sacubitril/valsartan or enalapril for 8 weeks, followed by an 8-week open-label phase with sacubitril/valsartan. Primary endpoint was change from baseline in mean activity counts during the most active 30 min/day at week 8...
September 26, 2020: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
Hongzhou Zhang, Tieqiu Huang, Wen Shen, Xiuxiu Xu, Pingping Yang, Dan Zhu, Haiyang Fang, Hongbing Wan, Tao Wu, Yanqing Wu, Qinghua Wu
AIMS: Sacubitril-valsartan has been shown to have superior effects over angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF) and hypertension. The efficacy and safety of sacubitril-valsartan in patients with HF are controversial. We performed a meta-analysis of randomized controlled trials to assess and compare the effect and adverse events of sacubitril-valsartan, valsartan, and enalapril in patients with HF. METHODS AND RESULTS: We conducted a systematic search using PubMed, Embase, the Cochrane Library, and ClinicalTrials...
September 25, 2020: ESC Heart Failure
Santiago Jiménez-Marrero, Cristina Enjuanes, Sergi Yun, Josep Comín-Colet
Background: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin-angiotensin-aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosilicate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients...
August 2020: European Heart Journal. Case Reports
Renato De Vecchis, Andrea Paccone
Anthracyclines are the cornerstone of treatment for many solid and hematological cancers such as breast cancer or lymphoma for the past 50 years. Nevertheless, in a non-negligible proportion of patients, they elicit dilated cardiomyopathy as a side effect, which causes in turn cardiac decompensation. Conversely, for some years, sacubitril/valsartan has been proposed as a new therapeutic paradigm for all varieties of heart failure with reduced left ventricular ejection fraction, due to its balanced enhancement of natriuretic peptides' properties coupled with a blocking effect on the AT1 angiotensin receptors...
2020: SAGE Open Medical Case Reports
Yen-Ling Sung, Ting-Tse Lin, Jhen-Yang Syu, Hung-Jui Hsu, Kai-Yuan Lin, Yen-Bin Liu, Shien-Fong Lin
AIMS: Hypertension is a significant risk for the development of left ventricular hypertrophy, diastolic dysfunction, followed by heart failure and sudden cardiac death. While therapy with sacubitril/valsartan (SV) reduces the risk of sudden cardiac death in patients with heart failure and systolic dysfunction, the effect on those with diastolic dysfunction remains unclear. We hypothesized that, in the animal model of hypertensive heart disease, treatment with SV reduces the susceptibility to ventricular arrhythmia...
September 24, 2020: ESC Heart Failure
Giuseppe Di Tano, Simone Verde, Marco Loffi, Renata De Maria, Gian Battista Danzi
BACKGROUND: During the COVID-19 pandemic, non-urgent outpatient activities were temporarily suspended. The aim of this study was to assess the impact of this measure on the management of the heart failure outpatient clinic at our institution. METHODS: We analyzed the clinical outcome of 110 chronic heart failure patients (mean age 73 ± 9 years) whose follow-up visit had been delayed. RESULTS: At their last visit before the lockdown, 80.9% was in NYHA class II, had an ejection fraction of 37 ± 7%, and B-type natriuretic peptide level was moderately elevated (266 ± 138 pg/ml)...
October 2020: Giornale Italiano di Cardiologia
P Lamendola, G A Lanza, V Melita, A Villano, C Palermo, D Leone, A Lombardo, F Pennestrì, F Crea, E M Mercuri, M Pane
OBJECTIVE: Duchenne muscular dystrophy (DMD) is an inherited X-linked recessive neuromuscular disease caused by mutations of the dystrophin gene, leading to early and progressive muscle deterioration and dilated cardiomyopathy. The aim of this investigation was to assess whether treatment with sacubitril/valsartan (S/V) is well tolerated and may have beneficial effects in DMD patients with left ventricle (LV) dysfunction. PATIENTS AND METHODS: We administered S/V to 3 DMD patients (19-29 yeard old) with LV ejection fraction <35% at echocardiography but no symptoms of heart failure...
September 2020: European Review for Medical and Pharmacological Sciences
Rafael de la Espriella, Antoni Bayés-Genís, Herminio Morillas, Rafael Bravo, Verónica Vidal, Eduardo Núñez, Enrique Santas, Gema Miñana, Juan Sanchis, Lorenzo Fácila, Francisco Torres, Jose Luis Górriz, Alfonso Valle, Julio Núñez
AIMS: The aim of this study was to evaluate the safety profile in terms of changes in renal function after co-treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS: This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23)...
September 22, 2020: ESC Heart Failure
Francesco Spannella, Federico Giulietti, Andrea Filipponi, Riccardo Sarzani
A worsening renal function is prevalent among patients with cardiovascular disease, especially heart failure (HF). Sacubitril/valsartan appears to prevent worsening of renal function and progression of chronic kidney disease (CKD) as compared with renin-angiotensin system (RAS) inhibitors alone in HF patients. It is unclear whether these advantages are present in HF patients only, or can be extended to other categories of patients, in which this drug was studied. We performed a systematic review and meta-analysis to assess the consistency of effect size regarding renal outcome across randomized controlled trials (RCTs) that compared sacubitril/valsartan with RAS inhibitors in patients with or without HF...
September 22, 2020: ESC Heart Failure
Marco Sbolli, Christopher deFilippi
PURPOSE OF REVIEW: Describe the mechanisms that may influence change in measured natriuretic peptide levels when using the neprilysin inhibitor sacubitril to treat a patient with heart failure. RECENT FINDINGS: Prior to the introduction of the neprilysin inhibitor sacubitril as part of a chemical combination with the angiotensin receptor blocker valsartan shown to reduce mortality and heart failure hospitalizations in patients with heart failure with reduced ejection fraction, the natriuretic peptide assays for B-type natriuretic peptide (BNP) and the amino-terminal proBNP (NT-proBNP) assays were shown to have similar diagnostic accuracy to differentiate heart failure from other etiologies of shortness of breath...
September 19, 2020: Current Cardiology Reports
Nasrien E Ibrahim, Ileana L Piña, Alexander Camacho, Devavrat Bapat, G Michael Felker, Alan S Maisel, Javed Butler, Margaret F Prescott, Cheryl A Abbas, Scott D Solomon, James L Januzzi
No abstract text is available yet for this article.
September 18, 2020: European Journal of Heart Failure
Jason Shafrin, Elmar R Aliyev, Michelle Brauer, Siyeon Park, Xian Shen
Aims : To understand the financial impact of health system adoption of novel heart failure medications under US alternative payment models (APMs). Materials and methods : This study used a decision tree model to assess the financial impact of health system adoption of sacubitril/valsartan to treat acute decompensated heart failure (ADHF). A comparator scenario modelled current health care utilization and cost for treating hospitalized ADHF patients with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB)...
September 18, 2020: Journal of Medical Economics
Amit K J Mandal, Constantinos G Missouris
No abstract text is available yet for this article.
September 8, 2020: Journal of Cardiovascular Medicine
Antonio Valentim Goncalves, Tiago Pereira-da-Silva, Ana Galrinho, Pedro Rio, Luísa Moura Branco, Rui Soares, Rita Ilhao Moreira, Rui Cruz Ferreira
OBJECTIVE: C-Reactive Protein (CRP) has emerged as an accessible measured product of inflammation. Whether systemic inflammation, a common feature of Heart Failure (HF), can be reduced by HF treatments in not well established. Sacubitril/Valsartan had prognosis benefit demonstrated in the PARADIGM-HF trial and was able to reduce proinflammatory cytokines in preclinical animal studies. However, no human studies evaluated if the benefits of this therapy are mediated by anti-inflammatory effects too...
2020: American Journal of Cardiovascular Disease
Luis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, Brian Claggett, Milton Packer, Akshay S Desai, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J V McMurray, Scott D Solomon
OBJECTIVES: The purpose of this study was to investigate the effect of sacubitril/valsartan therapy on sudden cardiac death (SCD) according to the use of and eligibility for an implantable cardioverter-defibrillator (ICD), stratified by heart failure cause. BACKGROUND: SCD still accounts for a significant proportion of overall mortality in heart failure with reduced ejection fraction (HFrEF). METHODS: Patients enrolled in the PARADIGM-HF (Prospective Comparison of ARNI with an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (n = 8,399) were evaluated to assess patterns of ICD implantation and eligibility according to clinical guidelines...
October 2020: JACC. Heart Failure
Cecilia Berardi, Eugene Braunwald, David A Morrow, Hillary S Mulder, Carol I Duffy, Terrence X O'Brien, Andrew P Ambrosy, Hrishikesh Chakraborty, Eric J Velazquez, Adam D DeVore
OBJECTIVES: This study compared the efficacy and safety of sacubitril/valsartan to enalapril in Black and non-Black Americans with acute decompensated heart failure (ADHF). BACKGROUND: Black patients have a different response to treatment with angiotensin-converting enzyme inhibitors compared with other racial and ethnic groups. How Black patients with ADHF respond to sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, is unclear. PIONEER-HF was a double-blind randomized clinical trial of sacubitril/valsartan versus enalapril in hospitalized patients with ADHF following hemodynamic stabilization...
October 2020: JACC. Heart Failure
Maria Rosa Costanzo
No abstract text is available yet for this article.
October 2020: JACC. Heart Failure
Kyeong-Hyeon Chun, Jaewon Oh, Hee Tae Yu, Chan Joo Lee, Tae-Hoon Kim, Jae Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung, Seok-Min Kang
AIMS: Optimal medical therapy after cardiac resynchronization therapy (CRT) implantation is important in heart failure (HF) with reduced ejection fraction (HFrEF) patients. Although sacubitril/valsartan (SV) is a mainstay in the treatment of HFrEF, its efficacy in the management of CRT non-responders has not been emphasized. We aimed to investigate the efficacy of SV in CRT non-responders. METHODS AND RESULTS: We analysed 175 HFrEF patients who received CRT implantation between January 2010 and January 2019...
September 11, 2020: ESC Heart Failure
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"